InnoCare Pharma Limited
INCPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $53,880 | $350,171 | $381,263 | $311,700 |
| % Growth | -84.6% | -8.2% | 22.3% | – |
| Cost of Goods Sold | $6,802 | $40,647 | $36,066 | $40,413 |
| Gross Profit | $47,078 | $309,524 | $345,197 | $271,287 |
| % Margin | 87.4% | 88.4% | 90.5% | 87% |
| R&D Expenses | $31,769 | $242,099 | $207,599 | $199,626 |
| G&A Expenses | $0 | $40,840 | $42,763 | $42,708 |
| SG&A Expenses | $26,354 | $170,993 | $156,536 | $189,552 |
| Sales & Mktg Exp. | $0 | $130,060 | $114,012 | $146,033 |
| Other Operating Expenses | $698 | -$56,288 | -$35,332 | $47,876 |
| Operating Expenses | $58,821 | $356,803 | $328,803 | $437,054 |
| Operating Income | -$11,742 | -$47,279 | $16,394 | -$165,767 |
| % Margin | -21.8% | -13.5% | 4.3% | -53.2% |
| Other Income/Exp. Net | $7,027 | $302 | $0 | -$1,537 |
| Pre-Tax Income | -$4,715 | -$46,978 | $16,394 | -$167,304 |
| Tax Expense | $381 | $3,136 | $1,919 | $234 |
| Net Income | -$4,817 | -$48,059 | $17,968 | -$165,223 |
| % Margin | -8.9% | -13.7% | 4.7% | -53% |
| EPS | -0.003 | -0.04 | 0.01 | -0.1 |
| % Growth | 93.2% | -496% | 110% | – |
| EPS Diluted | -0.003 | -0.04 | 0.01 | -0.1 |
| Weighted Avg Shares Out | 1,762,958 | 1,212,387 | 1,796,763 | 1,615,036 |
| Weighted Avg Shares Out Dil | 1,762,958 | 1,212,378 | 1,796,763 | 1,615,032 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,280 | $24,869 | $30,699 | $23,818 |
| Interest Expense | $2,034 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $19,597 | $16,756 | $16,756 |
| EBITDA | -$2,639 | -$88,695 | -$3,259 | -$121,475 |
| % Margin | -4.9% | -25.3% | -0.9% | -39% |